chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 71-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 03Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 70 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 02Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Hypothroidism" (unspecified if ongoing); "sulfa allergy" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE; SIMVASTATIN. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: COVID 19 Treatment; (03Jul2022) Positive, notes: Sunday, July 3 (5th day of Paxlovid): Positive rapid antigen test around 8:10 am; (06Jul2022) Negative, notes: Wednesday, 6Jul: I feel pretty darn good Negative rapid antigen test taken about 9:40 AM; (12Jul2022) Positive, notes: Tuesday, 12Jul: Positive rapid antigen test at 10 am. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Continued mild symptoms- scratchy (and occasionally sore) throat. It was still hard to fall asleep last night. Patient feel like she had a mild cold. Her head was stuffy. That was her only symptom. She really thought she was going to test negative because she attributes the cold to two consecutive nights of abysmal sleep.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
8 days after the vaccination, the area of the inoculation became red, warm to the touch and itchy.  At times there is a circle around the injection site that is normal skin color and a redish pink area surrounding that circle, and a swarth of patchy redness on the upper side of the arm extending to just above the elbow.  It is itchy.   At other times, the entire area is pink and itchy.  This has been going on as of this writing  for 9 days.  Saw my cardiologist today, advised to see my PCP.  Have an appointment  3/24/21.    Should I get the second shot on April 2nd?
This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (scheduled to receive her 2nd dose on 02apr2021) in a 93-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     No medical history were provided by the reporter.     On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (scheduled to receive her 2nd dose on 02apr2021). At the time of the report, PRODUCT DOSE OMISSION ISSUE (scheduled to receive her 2nd dose on 02apr2021) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication information was provided by the reporter. No lab data has been provided by the reporter.
pt devel chickenpox via secondary transmission;30SEP97 pt sibling recv vax;
In her Left Clavicle a knout (like a bump); Minor injection site pain (L arm); This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Minor injection site pain (L arm)) and LYMPHADENOPATHY (In her Left Clavicle a knout (like a bump)) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced VACCINATION SITE PAIN (Minor injection site pain (L arm)). On 17-Mar-2021, the patient experienced LYMPHADENOPATHY (In her Left Clavicle a knout (like a bump)). At the time of the report, VACCINATION SITE PAIN (Minor injection site pain (L arm)) and LYMPHADENOPATHY (In her Left Clavicle a knout (like a bump)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included unspecified asthma inhaler (occasionally). The patient did not receive any treatment medications.
This spontaneous report as received from a healthcare worker refers to a male patient of unknown age. The patient's medical history and current conditions were not provided. On 23-JUL-2015, the patient was vaccinated with a first dose of VAQTA (lot #, expiration date, dose and route were not reported). On 21-SEP-2015, the patient was vaccinated with a second dose of VAQTA (lot #, expiration date, dose and route were not reported) which was outside of the recommendations in the VAQTA prescribing information. No adverse effect has been reported. This is one of two reports received from the same reporter. Additional information is not expected due to no consent to contact Health Care Professional was given.
Began with headaches and nausea. Around 5:30 headache pain escalated still with nausea. Took a 2 hr nap to see if headache would subside. Around 7:30 pm chest pain began, sweating and shortness of breath. 911 was called around 8pm. Firemen arrived first took blood pressure was very high and now was lethargic. Chest pain tightness & shortness of breath was still present upon paramedics arrival. Before heading to hospital paramedics administered oxygen and started IV.
After receiving the vaccine (while patient in the waiting area), her father indicated he needed our help as she wasn't feeling well. Upon inspection, patient was pale, clammy and stated she had ringing in her ears. We helped her lay down on the ground, and placed an ice pack under her neck. Patient never lost consciousness, but again stated "it is hard to hear." We added a second ice pack to her wrists. After about 3-5 minutes, patient stated she felt much better. We helped her to a sitting position on the floor, and gave her some water. She said she no longer had  ringing in her ears and was feeling much better. After about 2 more minutes, we helped her to a seated position on a bench. She stayed there for about 5 more minutes, then stated she felt "fine and normal."  Patient then left the pharmacy with her father.
vaccine given to a 16 year old; This spontaneous case was reported by a nurse and describes the occurrence of OFF LABEL USE (vaccine given to a 16 year old) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 19-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 16-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 19-Jul-2021, the patient experienced OFF LABEL USE (vaccine given to a 16 year old). At the time of the report, OFF LABEL USE (vaccine given to a 16 year old) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided by reporter.  No treatment medication was provided by reporter.  The lot number of the vaccine is 041B21A.
Patient was diagnosed with a DVT. Also had symptoms of nausea and vomiting which preceded the vaccine.
Shortly after vaccination, patient developed hives and tongue swelling. EMS at the site treated with 50mg benadryl, 125mg solu-medrol, and patient was transported to ER.
Severe pain neck - shoulders - joints - arms - wrists - hands - fingers. Weakness in legs.
Throbbing pain in left shoulder that began approximately 24 hours after initial dose of SHINGRIX. Increases with movement (becomes a sharp pain). Patient believes she's lost a bit of her range of motion in the affected joint. Was stable up until patient received second dose of SHINGRIX 11/14/18. Patient received second dose in right arm and indicated that it is pain free at this time but that pain returned and significantly worsened in left shoulder. Patient has been taking ibuprofen 800mg at bedtime since administration of second dose. She has an appointment with PCP 12/3/18.
Patient reports the day after her third Pfizer covid 19 immunization, booster her right face was paralyzed
No adverse event; Patient was given a 0.25 mL of Moderna Bivalent Booster instead of a 0.5ml dose / Invalid Bivalent Dose Administered; This spontaneous case was reported by a nurse and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient was given a 0.25 mL of Moderna Bivalent Booster instead of a 0.5ml dose / Invalid Bivalent Dose Administered) and NO ADVERSE EVENT (No adverse event) in a 61-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7147B) for COVID-19 prophylaxis.     Patient does not have any known drug allergies. No chronic and acute illness at the time of vaccination and one month prior.     On 15-Sep-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .25 milliliter. On 15-Sep-2022, the patient experienced ACCIDENTAL UNDERDOSE (Patient was given a 0.25 mL of Moderna Bivalent Booster instead of a 0.5ml dose / Invalid Bivalent Dose Administered). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Patient was given a 0.25 mL of Moderna Bivalent Booster instead of a 0.5ml dose / Invalid Bivalent Dose Administered) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related and ACCIDENTAL UNDERDOSE (Patient was given a 0.25 mL of Moderna Bivalent Booster instead of a 0.5ml dose / Invalid Bivalent Dose Administered) to have an unknown relationship.    No prescriptions, over the counter medications, dietary supplements or herbal medicines being taken at the time of vaccination and or at the time of adverse event.  It was reported that the patient was given a 0.25 mL of Moderna Bivalent Booster dose on 15-Sep-2022. Patient documentation showed the lot number for bivalent.  The information was presented to staff on 27-Sep-2022. The patient was called on 28-Sep-2022. Patient was made aware that patient received a 0.25 mL of Moderna Bivalent Booster dose. Patient verbalized understanding. Patient denied having distress at the time of call. Patient denied having to go to the emergency room  or primary care provider. Informed the patient according to Moderna the recommendation was to re vaccinate with full dose in 8 weeks from 15-Sep-2022. Patient stated that patient would like to be re vaccinated. Patient  was made aware and would reach out to patient regarding receiving full vaccination.  Treatment information was not provided.
Patient received the vaccine. Patient got very dizzy shortly thereafter. He started vomiting and slumped his head over in the trash can. BP was 98/58 with pulse of 56. Oxygen was 99. We got him to a hospital bed. 5 minutes later his bp was 102/60 with HR of 68.  Pulse was now 79 and oxygen 99. 10 minutes out, his bp was 101/65 with a pulse of 72.
Runny nose; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (Runny nose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RHINORRHOEA (Runny nose). At the time of the report, RHINORRHOEA (Runny nose) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications provided . No treatment information provided.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported event, a causal relationship cannot be excluded.
Red, itchy rash on legs and arms.  It started four and a half days after the 2nd COVID vaccination.   It  lasted approximately 2 days.  I treated it with hydrocortisone cream which reduced the itchiness somewhat.
Received T.C. from pt. Pt. states 3 hours after receiving flu vaccination she began to experience respiratory difficulty, congestion, cough with "some blood" chills, body aches, L arm pain (no redness) reddened eyes and throat "closing". Pt. self-administered BENADRYL with relief and went home from work to rest. I advised pt. to notify primary care M.D of episode. Pt. feeling "better" on 11-3-10 - resting at home. 11-3-10 TC to pt. - feeling better - discussion with pt. re: allergy consult. 11-8-10 TC to pt. to check pt's status. Pt. states she saw an allergist at the request of her primary care M.D. Pt. states allergist felt perhaps she had been exposed to illness prior to receiving the Flu vaccination - a co-worker had been ill, and that this was not a reaction to the Flu vaccine. Pt. now feeling "great". I strongly encourage to pt., as did the Allergist, to received future Flu vaccination in a more controlled medical' setting.
Soreness of arm injection site; Headache; Tired; Feeling sick; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old, non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown), via an unspecified route of administration in left arm on 23Mar2021 at 08:45 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. The patient had no known allergies. The patient had no medical history. It was reported that the patient received unspecified medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021 at 20:00, the patient experienced soreness of arm on injection site, headache, tiredness and feeling sick. The patient did not receive treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event soreness of arm on vaccination site, headache, tiredness and feeling sick were recovering at the time of this report.    No follow-up attempts are possible; information about lot number cannot be obtained.
"Pimple-like" rash on chest, arms, back. No fever. No aches.
It started with aches, I thought I had the flew. I had back ache, skin sensitivity, loss of appetite, zero energy. Getting up to use the restroom was a big effort. I also had a constant cough. It stayed that way for about two weeks. I had been trying to contact my doctor for PAXLOVID but I didn't get through to anyone. I called the nurse advice line and they managed to get me a prescription for PAXLOVID. I was then contacted by a clinic telling me that I was approved but I had to be there within an hour and a half so I didn't end up getting it. On 10/1/2022 I tested negative.
States redness and itching started Nov 7th on (R) arm at site of influenza vaccine (received Nov 6 2013) and gradually spread down arm, across torso to entire body. 11/19/2013: Dermatitis, perhaps reactive (pt mentioned that this started just distal to flu vaccine site): SOLU-MEDROL IM. Prednisone taper. Topical steroid. Antihistamine. Instructed pt to call if not improved. Methylprednisolone 125 mg once, Prednisone taper (70mg to 10mg) over 7 da mg every day, diphenhydramine 25 mg PRN.
Systemic: Other- Bells Palsey diagnosed 1/26/21 at hospital
Immediate pain in the shoulder upon injection, unlike any previous vaccinations received. Injection was given higher than any previous influenza injections which had been in the deltoid muscle. Pharmacist did not palpate arm to locate muscle nor did he push shirt sleeve up to fully visualize upper arm. Pain was acute and continued to be acute for several weeks. Pain was felt at rest for 1 week and upon activities of daily living for at least 2 months (lifting arm to bathe or dress, using arm when turning automobile steering wheel, etc.). Patient was evaluated by primary physician on Oct. 12, 2018 due to severity of pain. He advised rest arm, take non-steroidal anti-inflammatories and to return if the shoulder pain did not resolve. Patient returned Nov. 1, 2018 as pain was not as excruciating but was still severe enough to interfere with or cause pain during previously routine activities. Patient consulted orthopedist Dr. on Nov. 13, 2018 who advised that any improvement was a good indication of eventual resolution, to continue to take non-steroidal anti-inflammatories and to return if there was not improvement. Shoulder pain has slowly improved, although it continues to cause pain in certain positions such as lifting the arm overhead or forward. As of the date of this report, Jan. 24, 2019, the shoulder pain has not fully resolved and care in activities as well as continued use of non-steroidal anti-inflammatories is still necessary.
30 minutes after receiving  the vaccine i started to have left chest and jaw pain that worsened over the next 10 minutes... i took 2 nitroglycerin 5 minutes apart and over the next  hour it mostly resolved called the cardiologists office told to go to ER with further symptoms. Spoke to my cardiologist the next day she said she had someone with similar symptoms  that went to the ER and workup was ok.
Rash; Dose received: 3; This is a spontaneous report from a non-contactable reporter (consumer or other non HCP). The reporter is the patient.  A 49-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in right arm, administration date 08Jan2022 at 14:45 (Lot number: unknown) at the age of 49 years as dose 3 (booster), single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot Number: UNKNOWN, Anatomical Location: Right arm, Administration time: 14:45), administration date: 03May2021, when the patient was 49 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot Number: UNKNOWN, Anatomical Location: Right arm, Administration time: 14:30), administration date: 28May2021, when the patient was 49 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 08Jan2022 at 14:45, outcome "unknown", described as "Dose received: 3"; RASH (non-serious) with onset 09Jan2022 at 09:00, outcome "not recovered", described as "Rash". Therapeutic measures were not taken as a result of rash.  Additional Information: The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
high pitched cry, lethargy, anorexia, repeated myoclonus; resolved in 36 hrs; poss szs, fever; started jerking;
mini-stroke; Could not keep my balance; This is a spontaneous report from a contactable consumer (patient). A 74-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Solution for injection), intramuscular, administered in the right arm, on 09Feb2021 10:00 (Batch/lot number: EL9269), at age 74 years old, as dose 1, single, for COVID-19 immunisation. Relevant medical history was reported as none. Concomitant medications included amlodipine besilate, olmesartan medoxomil (AZOR) and potassium chloride both taken for unknown indications, start and stop dates not reported. The patient did not receive any other vaccines within 4 weeks prior to BNT162B2. On 09Feb2021 11:00, 1 hour after the first vaccination, the patient could not keep his balance. The patient underwent MRI on an unspecified date which showed a mini stroke. The patient underwent COVID-19 test on 19Jan2021 which was negative. The patient then received the second dose of BNT162B2 on 02Mar2021 10:00 (Batch/lot number: EN6189), intramuscular in the left arm. The outcome of the events was unknown.  No follow-up attempts are needed. No further information is expected.